Issues and legislation related to access to gene therapies and treatment of rare diseases.
2026 · 3rd Quarter (July 1 - Sep 30)
GENETIX BIOTHERAPEUTICS, INC.
Filed by ARNOLD & PORTER KAYE SCHOLER LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- ARNOLD & PORTER KAYE SCHOLER LLP
- Filing UUID
- ea9c187c-d414-488a-8f54-8c6ec21e744b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to regulatory incentives for rare disease therapies.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.